Differential associations of angiographic extent and severity of coronary artery disease with asymmetric dimethylarginine but not insulin resistance in non-diabetic men with stable angina: A cross-sectional study

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Kruszelnicka, Olga ^a   Surdacki, Andrzej ^b   Golay, Alain ^c  

^a Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

ADMA; Coronary artery disease; Insulin resistance

Indexed keywords

INSULIN; N(G),N(G) DIMETHYLARGININE;

ADULT; ANGIOCARDIOGRAPHY; ARTERY DIAMETER; ARTICLE; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; GENSINI SCORE; HEART FAILURE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NONLINEAR SYSTEM; SCORING SYSTEM; STABLE ANGINA PECTORIS; SULLIVAN EXTENT SCORE;

ADULT; AGED; ANGINA, STABLE; ARGININE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; HUMANS; INSULIN; INSULIN RESISTANCE; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84885058865     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-145     Document Type: Article

References (87)

1. Böger RH, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 2009, 60:481-487. 10.1016/j.phrs.2009.07.001, 19596069.
2. Jacobi J, Maas R, Cardounel AJ, Arend M, Pope AJ, Cordasic N, Heusinger-Ribeiro J, Atzler D, Strobel J, Schwedhelm E, Böger RH, Hilgers KF. Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine. Am J Pathol 2010, 176:2559-2570. 10.2353/ajpath.2010.090614, 2861120, 20348244.
3. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999, 99:1141-1146. 10.1161/01.CIR.99.9.1141, 10069780.
4. Furuki K, Adachi H, Matsuoka H, Enomoto M, Satoh A, Hino A, Hirai Y, Imaizumi T. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study. Atherosclerosis 2007, 191:206-210. 10.1016/j.atherosclerosis.2006.03.022, 16672157.
5. Maas R, Xanthakis V, Polak JF, Schwedhelm E, Sullivan LM, Benndorf R, Schulze F, Vasan RS, Wolf PA, Böger RH, Seshadri S. Association of the endogenous nitric oxide synthase inhibitor ADMA with carotid artery intimal media thickness in the Framingham Heart Study offspring cohort. Stroke 2009, 40:2715-2719. 10.1161/STROKEAHA.109.552539, 2749947, 19498184.
6. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich J, Böger R. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001, 358:2113-2117. 10.1016/S0140-6736(01)07217-8, 11784625.
7. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Münzel T. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005, 97:e53-e59. 10.1161/01.RES.0000181286.44222.61, 16100045.
8. Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR, März W. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 2007, 53:273-283.
9. Wang Z, Tang WH, Cho L, Brennan DM, Hazen SL. Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition. Arterioscler Thromb Vasc Biol 2009, 29:1383-1391. 10.1161/ATVBAHA.109.185645, 2755199, 19542023.
10. Lu TM, Chung MY, Lin MW, Hsu CP, Lin SJ. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. Int J Cardiol 2011, 153:135-140. 10.1016/j.ijcard.2011.06.120, 21794936.
11. Lu TM, Ding YA, Charng MJ, Lin SJ. Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease. Clin Cardiol 2003, 26:458-464. 10.1002/clc.4960261006, 14579916.
12. Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, Schmidt-Lucke C, Kusus M, Maas R, Schwedhelm E, Strödter D, Simon BC, Mügge A, Daniel WG, Tillmanns H, Maisch B, Streichert T, Böger RH. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006, 152:493.e1-493.e8.
13. Thum T, Tsikas D, Stein S, Schultheiss M, Eigenthaler M, Anker SD, Poole-Wilson PA, Ertl G, Bauersachs J. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 2005, 46:1693-1701. 10.1016/j.jacc.2005.04.066, 16256870.
14. Borgeraas H, Strand E, Ringdal Pedersen E, Dierkes J, Ueland PM, Seifert R, Wilberg ER, Bohov P, Berge RK, Nilsen DW, Nygård O. Omega-3 status and the relationship between plasma asymmetric dimethylarginine and risk of myocardial infarction in patients with suspected coronary artery disease. Cardiol Res Pract 2012, 2012:201742. 3549394, 23346455.
15. Després JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952-957. 10.1056/NEJM199604113341504, 8596596.
16. Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 1998, 83:2773-2776. 10.1210/jc.83.8.2773, 9709945.
17. Tenenbaum A, Adler Y, Boyko V, Tenenbaum H, Fisman EZ, Tanne D, Lapidot M, Schwammenthal E, Feinberg MS, Matas Z, Motro M, Behar S. Insulin resistance is associated with increased risk of major cardiovascular events in patients with preexisting coronary artery disease. Am Heart J 2007, 153:559-565. 10.1016/j.ahj.2007.01.008, 17383294.
18. Ausk KJ, Boyko EJ, Ioannou GN. Insulin resistance predicts mortality in nondiabetic individuals in the U.S. Diabetes Care 2010, 33:1179-1185. 10.2337/dc09-2110, 2875420, 20200308.
19. Gast KB, Tjeerdema N, Stijnen T, Smit JW, Dekkers OM. Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis. PLoS One 2012, 72:e52036.
20. Eddy D, Schlessinger L, Kahn R, Peskin B, Schiebinger R. Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis. Diabetes Care 2009, 32:361-366. 2628708, 19017770.
21. Negri M, Sheiban I, Arigliano PL, Tonni S, Montresor G, Carlini S, Manzato F. Interrelation between angiographic severity of coronary artery disease and plasma levels of insulin, C-peptide and plasminogen activator inhibitor-1. Am J Cardiol 1993, 72:397-401. 10.1016/0002-9149(93)91129-6, 8352181.
22. Solymoss BC, Marcil M, Chaour M, Gilfix BM, Poitras AM, Campeau L. Fasting hyperinsulinism, insulin resistance syndrome, and coronary artery disease in men and women. Am J Cardiol 1995, 76:1152-1156. 10.1016/S0002-9149(99)80326-9, 7484901.
23. Shinozaki K, Suzuki M, Ikebuchi M, Hara Y, Harano Y. Demonstration of insulin resistance in coronary artery disease documented with angiography. Diabetes Care 1996, 19:1-7. 10.2337/diacare.19.1.1, 8720524.
24. Takezako T, Saku K, Zhang B, Shirai K, Arakawa K. Insulin resistance and angiographical characteristics of coronary atherosclerosis. Jpn Circ J 1999, 63:666-673. 10.1253/jcj.63.666, 10496480.
25. Kwon K, Choi D, Koo BK, Ryu SK. Decreased insulin sensitivity is associated with the extent of coronary artery disease in patients with angina. Diabetes Obes Metab 2005, 7:579-585. 10.1111/j.1463-1326.2004.00438.x, 16050951.
26. Granér M, Syvänne M, Kahri J, Nieminen MS, Taskinen MR. Insulin resistance as predictor of the angiographic severity and extent of coronary artery disease. Ann Med 2007, 39:137-144. 10.1080/07853890601083451, 17453676.
27. Anuurad E, Tracy RP, Pearson TA, Kim K, Berglund L. Synergistic role of inflammation and insulin resistance as coronary artery disease risk factors in African Americans and Caucasians. Atherosclerosis 2009, 205:290-295. 10.1016/j.atherosclerosis.2008.11.028, 2700183, 19135196.
28. Vonbank A, Saely CH, Rein P, Beer S, Breuss J, Boehnel C, Drexel H. Insulin resistance is associated with the metabolic syndrome and is not directly linked to coronary artery disease. Clin Chim Acta 2011, 412:1003-1007. 10.1016/j.cca.2011.02.008, 21320476.
29. An X, Yu D, Zhang R, Zhu J, Du R, Shi Y, Xiong X. Insulin resistance predicts progression of de novo atherosclerotic plaques in patients with coronary heart disease: a one-year follow-up study. Cardiovasc Diabetol 2012, 11:71. 10.1186/1475-2840-11-71, 3441242, 22709409.
30. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Böger RH, Bode-Böger SM, Kruszelnicka-Kwiatkowska O, Kokot F, Dubiel JS, Frölich JC. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999, 33:652-658. 10.1097/00005344-199904000-00020, 10218738.
31. Stühlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002, 287:1420-1426. 10.1001/jama.287.11.1420, 11903029.
32. Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 2003, 166:279-284. 10.1016/S0021-9150(02)00206-X, 12535740.
33. McLaughlin T, Stühlinger M, Lamendola C, Abbasi F, Bialek J, Reaven GM, Tsao PS. Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. J Clin Endocrinol Metab 2006, 91:1896-1900. 10.1210/jc.2005-1441, 16507636.
34. Marliss EB, Chevalier S, Gougeon R, Morais JA, Lamarche M, Adegoke OA, Wu G. Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia 2006, 49:351-359. 10.1007/s00125-005-0066-6, 16369774.
35. Surdacki A, Stochmal E, Szurkowska M, Bode-Böger SM, Martens-Lobenhoffer J, Stochmal A, Klecha A, Kawecka-Jaszcz K, Dubiel JS, Huszno B, Szybiński Z. Nontraditional atherosclerotic risk factors and extent of coronary atherosclerosis in patients with combined impaired fasting glucose and impaired glucose tolerance. Metabolism 2007, 56:77-86. 10.1016/j.metabol.2006.08.023, 17161229.
36. Zsuga J, Torok J, Magyar MT, Valikovics A, Gesztelyi R, Lenkei A, Csiba L, Kéki S, Zsuga M, Bereczki D. Dimethylarginines at the crossroad of insulin resistance and atherosclerosis. Metabolism 2007, 56:394-399. 10.1016/j.metabol.2006.10.023, 17292729.
37. Schutte AE, Schutte R, Huisman HW, van Rooyen JM, Fourie CM, Malan L, Malan NT, Schwedhelm E, Strimbeanu S, Anderssohn M, Böger RH. Dimethylarginines: their vascular and metabolic roles in Africans and Caucasians. Eur J Endocrinol 2010, 162:525-533. 10.1530/EJE-09-0865, 19996198.
38. Perticone F, Sciacqua A, Maio R, Perticone M, Galiano Leone G, Bruni R, Di Cello S, Pascale A, Talarico G, Greco L, Andreozzi F, Sesti G. Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int J Cardiol 2010, 142:236-241. 10.1016/j.ijcard.2008.12.131, 19168237.
39. Lu TM, Lin SJ, Lin MW, Hsu CP, Chung MY. The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: a cohort study. Cardiovasc Diabetol 2011, 10:16. 10.1186/1475-2840-10-16, 3050685, 21303562.
40. Andreozzi F, Presta I, Mannino GC, Scarpelli D, Di Silvestre S, Di Pietro N, Succurro E, Sciacqua A, Pandolfi A, Consoli A, Hribal ML, Perticone F, Sesti G. A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with insulin sensitivity. PLoS One 2012, 7:e36224. 10.1371/journal.pone.0036224, 3338696, 22558392.
41. Işi{dotless}klar OO, Barutcuoǧlu B, Kabaroǧlu C, Mutaf I, Özmen D, Bayi{dotless}ndi{dotless}r O, Zoghi M, Uluer H. Do cardiac risk factors affect the homocysteine and asymmetric dimethylarginine relationship in patients with coronary artery diseases?. Clin Biochem 2012, 45:1325-1330. 10.1016/j.clinbiochem.2012.06.024, 22750146.
42. Dimitroulas T, Sandoo A, Veldhuijzen van Zanten JJ, Smith JP, Hodson J, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD. Predictors of asymmetric dimethylarginine levels in patients with rheumatoid arthritis: the role of insulin resistance. Scand J Rheumatol 2013, 42:176-181. 10.3109/03009742.2012.747627, 23311682.
43. Surdacki A, Kruszelnicka O, Rakowski T, Jażwińska-Kozuba A, Dubiel JS. Asymmetric dimethylarginine predicts decline of glucose tolerance in men with stable coronary artery disease: a 4.5-year follow-up study. Cardiovasc Diabetol 2013, 12:64. 10.1186/1475-2840-12-64, 3642017, 23578341.
44. Levey AS, Greene T, Kusek J, Beck G. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000, 11:155A.
45. Surdacki A, Marewicz E, Wieteska E, Szastak G, Rakowski T, Wieczorek-Surdacka E, Dudek D, Pryjma J, Dubiel JS. Association between endothelial progenitor cell depletion in blood and mild-to-moderate renal insufficiency in stable angina. Nephrol Dial Transplant 2008, 23:2265-2273. 10.1093/ndt/gfm943, 18187495.
46. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostatic model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419. 10.1007/BF00280883, 3899825.
47. Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP, Böger RH. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med 2004, 42:1377-1383.
48. Ringqvist I, Fisher LD, Mock M, Davis KB, Wedel H, Chaitman BR, Passamani E, Russell RO, Alderman EL, Kouchoukas NT, Kaiser GC, Ryan TJ, Killip T, Fray D. Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS). J Clin Invest 1983, 71:1854-1866. 10.1172/JCI110941, 370391, 6863543.
49. Sullivan DR, Marwick TH, Freedman SB. A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J 1990, 119:1262-1267. 10.1016/S0002-8703(05)80173-5, 1972310.
50. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983, 51:606. 10.1016/S0002-9149(83)80105-2, 6823874.
51. Neeland IJ, Patel RS, Eshtehardi P, Dhawan S, McDaniel MC, Rab ST, Vaccarino V, Zafari AM, Samady H, Quyyumi AA. Coronary angiographic scoring systems: an evaluation of their equivalence and validity. Am Heart J 2012, 164:547-552.e1. 10.1016/j.ahj.2012.07.007, 23067913.
52. Siegerink B, Maas R, Vossen CY, Schwedhelm E, Koenig W, Böger R, Rothenbacher D, Brenner H, Breitling LP. Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study. Clin Res Cardiol 2013, 102:193-202. 10.1007/s00392-012-0515-4, 23073705.
53. Ambrose JA, Tannenbaum MA, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, Borrico S, Gorlin R, Fuster V. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988, 12:56-62. 10.1016/0735-1097(88)90356-7, 3379219.
54. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, Santamore WP. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease?. Circulation 1988, 78(5 Pt 1):1157-1166.
55. Tousoulis D, Davies G, Crake T, Lefroy DC, Rosen S, Maseri A. Angiographic characteristics of infarct-related and non-infarct-related stenoses in patients in whom stable angina progressed to acute myocardial infarction. Am Heart J 1998, 136:382-388. 10.1016/S0002-8703(98)70210-8, 9736127.
56. Yamagishi M, Terashima M, Awano K, Kijima M, Nakatani S, Daikoku S, Ito K, Yasumura Y, Miyatake K. Morphology of vulnerable coronary plaque: insights from follow-up of patients examined by intravascular ultrasound before an acute coronary syndrome. J Am Coll Cardiol 2000, 35:106-111. 10.1016/S0735-1097(99)00533-1, 10636267.
57. Bigi R, Cortigiani L, Colombo P, Desideri A, Bax JJ, Parodi O. Prognostic and clinical correlates of angiographically diffuse non-obstructive coronary lesions. Heart 2003, 89:1009-1013. 10.1136/heart.89.9.1009, 1767817, 12923011.
58. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 2000, 23:171-175. 10.2337/diacare.23.2.171, 10868826.
59. Kruszelnicka-Kwiatkowska O, Surdacki A, Goldsztajn P, Matysek J, Piwowarska W, Golay A. Relationship between hyperinsulinemia and angiographically defined coronary atherosclerosis in non-diabetic men. Diabetes Metab 2002, 28(4 Pt 1):305-309.
60. Blaha MJ, DeFilippis AP, Rivera JJ, Budoff MJ, Blankstein R, Agatston A, Szklo M, Lakoski SG, Bertoni AG, Kronmal RA, Blumenthal RS, Nasir K. The relationship between insulin resistance and incidence and progression of coronary artery calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2011, 34:749-751. 10.2337/dc10-1681, 3041221, 21292863.
61. Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H. The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 2005, 90:5698-5703. 10.1210/jc.2005-0799, 16091486.
62. Yanase M, Takatsu F, Tagawa T, Kato T, Arai K, Koyasu M, Horibe H, Nomoto S, Takemoto K, Shimizu S, Watarai M. Insulin resistance and fasting hyperinsulinemia are risk factors for new cardiovascular events in patients with prior coronary artery disease and normal glucose tolerance. Circ J 2004, 68:47-52. 10.1253/circj.68.47, 14695465.
63. Sekiguchi M, Kurabayashi M, Adachi H, Hoshizaki H, Oshima S, Taniguchi K. Usefulness of insulin resistance measured by homeostasis model assessment in predicting restenosis after coronary stent placement in nondiabetic patients. Am J Cardiol 2004, 93:920-922. 10.1016/j.amjcard.2003.12.036, 15050499.
64. Nishio K, Fukui T, Tsunoda F, Kawamura K, Itoh S, Konno N, Ozawa K, Katagiri T. Insulin resistance as a predictor for restenosis after coronary stenting. Int J Cardiol 2005, 103:128-134. 10.1016/j.ijcard.2004.08.039, 16080969.
65. Sydow K, Mondon CE, Cooke JP. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA. Vasc Med 2005, 10(Suppl 1):S35-S43.
66. Al Suwaidi J, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000, 101:948-954. 10.1161/01.CIR.101.9.948, 10704159.
67. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000, 101:1899-1906. 10.1161/01.CIR.101.16.1899, 10779454.
68. Sydow K, Mondon CE, Schrader J, Konishi H, Cooke JP. Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity. Arterioscler Thromb Vasc Biol 2008, 28:692-697. 10.1161/ATVBAHA.108.162073, 3165027, 18239148.
69. Eid HM, Reims H, Arnesen H, Kjeldsen SE, Lyberg T, Seljeflot I. Decreased levels of asymmetric dimethylarginine during acute hyperinsulinemia. Metabolism 2007, 56:464-469. 10.1016/j.metabol.2006.11.003, 17379002.
70. Marcovecchio ML, Widmer B, Dunger DB, Dalton RN. Effect of acute variations of insulin and glucose on plasma concentrations of asymmetric dimethylarginine in young people with type 1 diabetes. Clin Sci 2008, 115:361-369. 10.1042/CS20080079, 18498242.
71. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003, 23:1455-1459. 10.1161/01.ATV.0000081742.92006.59, 12805079.
72. Wang D, Gill PS, Chabrashvili T, Onozato ML, Raggio J, Mendonca M, Dennehy K, Li M, Modlinger P, Leiper J, Vallance P, Adler O, Leone A, Tojo A, Welch WJ, Wilcox CS. Isoform-specific regulation by NG, NG-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res 2007, 101:627-635. 10.1161/CIRCRESAHA.107.158915, 17673667.
73. Surdacki A. L-arginine analogs - inactive markers or active agents in atherogenesis?. Cardiovasc Hematol Agents Med Chem 2008, 6:302-311. 10.2174/187152508785909429, 18855643.
74. Maas R, Erdmann J, Lüneburg N, Stritzke J, Schwedhelm E, Meisinger C, Peters A, Weil J, Schunkert H, Böger RH, Lieb W. Polymorphisms in the promoter region of the dimethylarginine dimethylaminohydrolase 2 gene are associated with prevalence of hypertension. Pharmacol Res 2009, 60:488-493. 10.1016/j.phrs.2009.07.013, 19666123.
75. Tessari P, Cecchet D, Artusi C, Vettore M, Millioni R, Plebani M, Puricelli L, Vedovato M. Roles of insulin, age, and asymmetric dimethylarginine, on nitric oxide synthesis in vivo. Diabetes 2013, 62:2699-2708. 10.2337/db12-1127, 23474488.
76. Baron AD, Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest 1995, 96:786-792. 10.1172/JCI118124, 185264, 7635973.
77. Petrie JR, Ueda S, Webb DJ, Elliott HL, Connell JM. Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation 1996, 93:1331-1333. 10.1161/01.CIR.93.7.1331, 8641020.
78. Cleland SJ, Petrie JR, Small M, Elliott HL, Connell JM. Insulin action is associated with endothelial function in hypertension and type 2 diabetes. Hypertension 2000, 35(1 Pt 2):507-511.
79. Utriainen T, Mäkimattila S, Virkamäki A, Bergholm R, Yki-Järvinen H. Dissociation between insulin sensitivity of glucose uptake and endothelial function in normal subjects. Diabetologia 1996, 39:1477-1482. 10.1007/s001250050601, 8960829.
80. Avogaro A, Piarulli F, Valerio A, Miola M, Calveri M, Pavan P, Vicini P, Cobelli C, Tiengo A, Calò L, Del Prato S. Forearm nitric oxide balance, vascular relaxation, and glucose metabolism in NIDDM patients. Diabetes 1997, 46:1040-1046. 10.2337/diab.46.6.1040, 9166677.
81. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Kruszelnicka-Kwiatkowska O, Kokot F, Dubiel JS, Frölich JC. Effects of acute euglycemic hyperinsulinemia on urinary nitrite/nitrate excretion and plasma endothelin-1 levels in men with essential hypertension and normotensive controls. Metabolism 1999, 48:887-891. 10.1016/S0026-0495(99)90224-X, 10421231.
82. Natali A, Ribeiro R, Baldi S, Tulipani A, Rossi M, Venturi E, Mari A, Macedo MP, Ferrannini E. Systemic inhibition of nitric oxide synthesis in non-diabetic individuals produces a significant deterioration in glucose tolerance by increasing insulin clearance and inhibiting insulin secretion. Diabetologia 2013, 56:1183-1191. 10.1007/s00125-013-2836-x, 23370528.
83. Protopsaltis I, Foussas S, Angelidi A, Gritzapis A, Sergentanis TN, Matsagos S, Tzirogiannis K, Panoutsopoulos GI, Dimitriadis G, Raptis S, Melidonis A. Impact of ADMA, endothelial progenitor cells and traditional cardiovascular risk factors on pulse wave velocity among prediabetic individuals. Cardiovasc Diabetol 2012, 11:141. 10.1186/1475-2840-11-141, 3527304, 23153108.
84. Zapolski T, Wysokiński A, Ksia{ogonek}żek A, Jaroszyński A. Left atrial volume index and aortic stiffness index in adult hemodialysed patients-link between compliance and pressure mediated by endothelium dysfunction; a cross-sectional study. BMC Cardiovasc Disord 2012, 12:100. 10.1186/1471-2261-12-100, 3519803, 23122326.
85. Delles C, Schneider MP, John S, Gekle M, Schmieder RE. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical NG, NG-dimethylarginine in human essential hypertension. Am J Hypertens 2002, 15:590-593. 10.1016/S0895-7061(02)02278-1, 12118904.
86. Reaven GM. What do we learn from measurements of HOMA-IR?. Diabetologia 2013, 56:1867-1868. 10.1007/s00125-013-2948-3, 23722624.
87. Kruszelnicka O. Nitric oxide vs insulin secretion, action and clearance. Diabetologia in press.